Skip to main content
. 2022 Oct 25;13:925377. doi: 10.3389/fphar.2022.925377

FIGURE 2.

FIGURE 2

Thyroid neoplasm reporting rates. The reporting rates of GLP-1RA-associated neoplasms were compared with different comparators in four models: 1) other drugs excluding GLP-1RA (non-GLP-1RA) without indication restrictions; 2) non-GLP-1RA when diabetes as an indication; 3) non-GLP-1RA when the indication is limited to diabetes while excluding all tumors, and all cases with GLP-1RA as the “primary suspect” drug; and 4) all cases combining other glucose-lowering drugs were excluded on the basis of model 3 for comparison.